Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incyte's book value per share for the quarter that ended in Mar. 2026 was MXN507.11.
During the past 12 months, Incyte's average Book Value Per Share Growth Rate was 48.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 31.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Incyte was 114.30% per year. The lowest was -113.90% per year. And the median was 18.75% per year.
Incyte's current price is MXN2036.00. Its book value per share for the quarter that ended in Mar. 2026 was MXN507.11. Hence, today's PB Ratio of Incyte is 4.01.
During the past 13 years, the highest P/B Ratio of Incyte was 67.19. The lowest was 2.15. And the median was 5.74.
Warning Sign:
Incyte Corp stock PB Ratio (=4.12) is close to 1-year high of 4.47.
Incyte (MEX:INCY) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Incyte Book Value per Share Related Terms
Incyte Book Value per Share Historical Data
* Premium members only.
The historical data trend for Incyte's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: Book Value per Share Comparison
For the Biotechnology subindustry, Incyte's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's PB Ratio distribution charts can be found below:
* The bar in red indicates where Incyte's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of MXN507.11 mean?
Incyte (MEX:INCY) has a Book Value per Share of MXN507.11 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Incyte and its competitors.
Is Incyte's Book Value per Share too high?
Incyte's current Book Value per Share is MXN507.11. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Book Value per Share compare to INSM and BNTX?
Incyte's Book Value per Share of MXN507.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Incyte and its competitors. Incyte's current Book Value per Share is MXN507.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,760.29, compared to a current price of MXN2,036.00 — trading 15.7% above its estimated fair value. The current Book Value per Share is MXN507.11. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Book Value per Share is MXN507.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN2,036.00 is trading 15.7% above its estimated GF Value™ of MXN1,760.29.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
Book Value per Share: MXN507.11
GF Value™: MXN1,760.29 vs. price of MXN2,036.00 (15.7% above fair value)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
